{"prompt": "['Takeda', 'Title: Study of the QOL evaluation of Trelagliptin in patient with type 2 Diabetes', 'mellitus (TRENDS)', 'NCT Number: NCT03014479', 'Protocol Approve Date: 05-Jul-2017', 'Certain information within this protocol has been redacted (ie, specific content is', 'masked irreversibly from view with a black/blue bar) to protect either personally', 'identifiable information or company confidential information.', 'This may include, but is not limited to, redaction of the following:', 'Named persons or organizations associated with the study.', 'Patient identifiers within the text, tables, or figures or in by-patient data listings.', 'Proprietary information, such as scales or coding systems, which are considered', 'confidential information under prior agreements with license holder.', 'Other information as needed to protect confidentiality of Takeda or partners,', 'personal information, or to otherwise protect the integrity of the clinical study.', 'If needed, certain appendices that contain a large volume of personally identifiable', 'information or company confidential information may be removed in their entirety if it', 'is considered that they do not add substantially to the interpretation of the data (eg,', \"appendix of investigator's curriculum vitae).\", 'Note; This document was translated into English as the language on original version', 'was Japanese.']['Trelagliptin-4002', 'Page 1 of 66', 'Version 2.0', 'July 5, 2017', 'PROTOCOL', 'Study of the QOL evaluation of TRElagliptiN in patient with type 2 DiabeteS mellitus', '(TRENDS)', 'Sponsor', 'Takeda Pharmaceutical Company Limited', '12-10 Nihonbashi 2-chome, Chuo-ku, Tokyo', 'Protocol number', 'Trelagliptin-4002', 'Version number/Revision number', 'Version 2.0', 'Study drug', 'Trelagliptin', 'Creation date', 'July 5, 2017', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 2 of 66', 'Version 2.0', 'July 5, 2017', 'CONFIDENTIAL PROPERTY', 'This document is a confidential communication of Takeda. Acceptance of this document constitutes', 'agreement by the potential recipient that no information contained herein will be published or', 'disclosed without written authorization from Takeda except to the extent necessary to obtain', 'informed consent from those study subjects to whom the drug may be administered. Furthermore,', 'the information is only intended for review and compliance by the recipient, his or her staff, and', 'applicable institutional review committee and regulatory agencies to enable conduction of the study.', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}